Human umbilical cord blood-mesenchymal stem cell derived exosomes as an efficient nanocarrier for Docetaxel and miR-125a: Formulation optimization and anti-metastatic behaviour
- PMID: 37001803
- DOI: 10.1016/j.lfs.2023.121621
Human umbilical cord blood-mesenchymal stem cell derived exosomes as an efficient nanocarrier for Docetaxel and miR-125a: Formulation optimization and anti-metastatic behaviour
Abstract
Aim: Exosomes, as a nanocarrier for the co-delivery of biologicals and small anticancer molecules is yet in its infancy. Herein, we investigated hUCBMSC derived exosomes as a biogenic nanocarrier for the co-delivery of tumor suppressor miR-125a and microtubule destabilizing Docetaxel (DTX) to target the proliferative and migratory aggressiveness of the murine TNBC 4T1 cells.
Main methods: In this study, hUCBMSCs from the human umbilical cord blood cells (hUCB) were successfully transfected with miR-125a. Thereafter, DTX was encapsulated into both non-transfected and transfected exosomes by optimized mild sonication-incubation technique. The anticancer efficiency of hUCBMSC Exo-DTX and miR-125a Exo-DTX was compared by MTT and morphometric assay. The prominent anti-metastatic behaviour of the latter was confirmed by in-vitro wound healing and transwell invasion assay. Further, the synergistic effect of miR-125a and DTX was confirmed by F-actin and nuclear degradation by confocal and FESEM assay.
Key findings: hUCBMSC exosomes exhibited DTX payload of 8.86 ± 1.97 ng DTX/ μg exosomes and miRNA retention capacity equivalent to 12.31 ± 5.73 %. The co-loaded formulation (miR-125a Exo-DTX) exhibited IC50 at 192.8 ng/ml in 4T1 cells, which is almost 2.36 folds' lower than the free DTX IC50 (472.8 ng/ml). Additionally, miR-125a Exo-DTX treatment caused wound broadening upto 6.14±0.38 % while treatment with free DTX and miR-125a exosomes alone caused 18.71±4.5 % and 77.36±10.4 % of wound closure respectively in 36 h. miR-125a Exo-DTX treatment further exhibited significantly reduced invasiveness of 4T1 cells (by 3.5 ± 1.8 %) along with prominent cytoskeletal degradation and nuclear deformation as compared to the miR-125a exosomes treated group. The miR-125a expressing DTX loaded exosomal formulation clearly demonstrated the synergistic apoptotic and anti-migratory efficiency of the miR-125a Exo-DTX.
Significance: The synergistic anticancer and anti-metastatic effect of miR-125a Exo-DTX was observed due to presence of both DTX and miR-125a as the cargo of hUCBMSC derived exosomes.
Keywords: Docetaxel; Exosomes; MSC; Metastasis; Multi-nucleation; miR-125a.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Exosomal fragment enclosed polyamine-salt nano-complex for co-delivery of docetaxel and mir-34a exhibits higher cytotoxicity and apoptosis in breast cancer cells.Sci Rep. 2024 Sep 17;14(1):21669. doi: 10.1038/s41598-024-72226-0. Sci Rep. 2024. PMID: 39289425 Free PMC article.
-
Macrophage derived Exosomal Docetaxel (Exo-DTX) for pro-metastasis suppression: QbD driven formulation development, validation, in-vitro and pharmacokinetic investigation.Eur J Pharm Biopharm. 2024 Feb;195:114175. doi: 10.1016/j.ejpb.2024.114175. Epub 2024 Jan 6. Eur J Pharm Biopharm. 2024. PMID: 38185191
-
Exosomal encapsulation of miR-125a-5p inhibited trophoblast cell migration and proliferation by regulating the expression of VEGFA in preeclampsia.Biochem Biophys Res Commun. 2020 May 7;525(3):646-653. doi: 10.1016/j.bbrc.2020.02.137. Epub 2020 Feb 28. Biochem Biophys Res Commun. 2020. PMID: 32122654
-
Nicorandil-Pretreated Mesenchymal Stem Cell-Derived Exosomes Facilitate Cardiac Repair After Myocardial Infarction via Promoting Macrophage M2 Polarization by Targeting miR-125a-5p/TRAF6/IRF5 Signaling Pathway.Int J Nanomedicine. 2024 Feb 29;19:2005-2024. doi: 10.2147/IJN.S441307. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38469055 Free PMC article.
-
Intratumoral Injection of Large Surface Area Microparticle Taxanes in Carcinomas Increases Immune Effector Cell Concentrations, Checkpoint Expression, and Synergy with Checkpoint Inhibitors: A Review of Preclinical and Clinical Studies.Oncol Ther. 2024 Mar;12(1):31-55. doi: 10.1007/s40487-024-00261-y. Epub 2024 Jan 30. Oncol Ther. 2024. PMID: 38289576 Free PMC article. Review.
Cited by
-
Therapeutic Efficacy and Promise of Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles in Aging and Age-Related Disorders.Int J Mol Sci. 2024 Dec 30;26(1):225. doi: 10.3390/ijms26010225. Int J Mol Sci. 2024. PMID: 39796081 Free PMC article. Review.
-
Exosomal fragment enclosed polyamine-salt nano-complex for co-delivery of docetaxel and mir-34a exhibits higher cytotoxicity and apoptosis in breast cancer cells.Sci Rep. 2024 Sep 17;14(1):21669. doi: 10.1038/s41598-024-72226-0. Sci Rep. 2024. PMID: 39289425 Free PMC article.
-
Bioengineered nanotechnology for nucleic acid delivery.J Control Release. 2023 Dec;364:124-141. doi: 10.1016/j.jconrel.2023.10.034. Epub 2023 Oct 27. J Control Release. 2023. PMID: 37879440 Free PMC article. Review.
-
Engineered Extracellular Vesicles as a New Class of Nanomedicine.Chem Bio Eng. 2024 Oct 28;2(1):3-22. doi: 10.1021/cbe.4c00122. eCollection 2025 Jan 23. Chem Bio Eng. 2024. PMID: 39975802 Free PMC article. Review.
-
Synergistic effect of human uterine cervical mesenchymal stem cell secretome and paclitaxel on triple negative breast cancer.Stem Cell Res Ther. 2024 Apr 25;15(1):121. doi: 10.1186/s13287-024-03717-0. Stem Cell Res Ther. 2024. PMID: 38664697 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources